University of Texas MD Anderson: Patients With Advanced BRCA-Mutated Breast Cancer Found No Overall Survival Benefit With Talazoparib
May 29, 2020
May 29, 2020
HOUSTON, Texas, May 29 -- The University of Texas's MD Anderson Cancer Center issued the following news release on May 26:
New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes. Most patients included in the study w . . .
New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes. Most patients included in the study w . . .